At present, the treatment of RA has entered into a comprehensive management strategy, which aims to slow down the progression of the disease, reduce the occurrence of pain and bone destruction, preserve the joint mobility of patients as much as possible, and avoid disability ( 10, 11). Like most other autoimmune diseases, RA is more common in women than in men in a ratio of 2-3:1 ( 9).Īlthough RA has a high disability rate and high prevalence, its pathogenesis is not fully understood. For example, the prevalence of RA in China is 0.2% to 4% ( 7), the number of patients is as high as 4 million, and the remission rate is roughly only 8.6% ( 8). The incidence of RA is 7 percent among Native Americans and 0.2 to 0.4 percent in some other countries ( 6). The prevalence of RA varies among different ethnic groups. RA can occur at any age, and its incidence begins to increase significantly at age 25 at age 55, the incidence of rheumatoid arthritis peaks ( 4, 5). It is the most common systemic irritant arthritis and is one of the world’s major public health challenges, affecting approximately 1% of the world’s population ( 3). It primarily affects the joints, but should be considered as a syndrome that includes extra-articular manifestations, such as rheumatoid nodules, pulmonary involvement, or vasculitis, as well as systemic comorbidities ( 1, 2). Rheumatoid arthritis (RA) is a chronic, systemic, highly disabling autoimmune disease with non-infectious, symmetrical, progressive polyarthritis as the main clinical manifestation.
0 Comments
Leave a Reply. |